Nonhuman primate responses to murine and humanized OKT4A.
A nonhuman primate antimurine response (MAMA) has been observed in 17 cynomolgus renal allograft recipients of murine OKT 4A. Neither cyclosporine, nor total-lymphoid irradiation, nor donor bone marrow preparation inhibited this antixenogeneic response. In an attempt to alter the antimurine basis of the response, a humanized chimeric OKT4A (IgG4) containing the entire variable portion of the murine OKT4A and a humanized CDR grafted OKT4A mAb sharing only the Complementarity Determining Region from the murine OKT4A, were administered to 8 cynomolgus allograft recipients. MAMA was detected in each recipient. In contrast to sera from recipients of murine OKT4A, sera from recipients of humanized OKT4A displayed no reactivity to other murine mAbs. MAMA specificity did not assay constant (C) region differences between the murine and humanized mAb; however, C region homology in humans should preclude a human antimouse antibody (HAMA) to the Fc portion of a humanized mAb. Furthermore, cynomolgus recipient serum levels of the humanized OKT4A mAb were maintained (> 1 microgram/ml) for a longer period than following treatment with murine OKT4A (murine < 12 days versus between 12 and 24 days for the humanized). If the HAMA response to humanized mAb in future clinical trials, were to be predictably anti-idiotypic, then the opportunity for treatment with sequential mAbs of differing idiotypes would be retained. Moreover, these current studies also suggest that humanized construction may influence the duration of therapeutic mAb levels. Thus, anti-idiotypic reactivity may not be as consequential to the clinical administration of humanized mAb to allograft recipients.
Delmonico
F L
FL
Transplantation Unit, Harvard Medical School, Massachusetts General Hospital, Boston 02114.
Cosimi
A B
AB
Kawai
T
T
Cavender
D
D
Lee
W H
WH
Jolliffe
L K
LK
Knowles
R W
RW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000276:immunology*; D000917:Antibody Formation; D000918:Antibody Specificity; D002678:Chimera; D003429:Cross Reactions; D016572:Cyclosporine / Q000627:therapeutic use; D007108:Immune Tolerance / Q000187:drug effects / Q000528:radiation effects; D016030:Kidney Transplantation / Q000276:immunology; D008221:Lymphoid Tissue / Q000528:radiation effects; D008252:Macaca fascicularis; D051379:Mice
D000911:Antibodies, Monoclonal; D016572:Cyclosporine